GRFS Stock Summary and Trading Ideas (Grifols S.A. - American Depositary Shares | NASDAQ:GRFS)

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

Grifols S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol GRFS.

As of April 19, 2024, GRFS stock price declined to $6.28 with 1,190,615 million shares trading.

GRFS has a beta of 1.03, meaning it tends to be more sensitive to market movements. GRFS has a correlation of 0.03 to the broad based SPY ETF.

GRFS has a market cap of $4.26 billion. This is considered a Mid Cap stock.

In the last 3 years, GRFS stock traded as high as $19.07 and as low as $5.30.

The top ETF exchange traded funds that GRFS belongs to (by Net Assets): IBB, SPDW, KOMP, BINV, BSMC.

GRFS has underperformed the market in the last year with a price return of -16.6% while the SPY ETF gained +21.2%. GRFS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -7.0% and -8.5%, respectively, while the SPY returned +4.3% and -3.5%, respectively.

GRFS support price is $6.30 and resistance is $6.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRFS stock will trade within this expected range on the day.